“PSMA Imaging in Prostate Cancer: New Developments”
With Dr. Michael Morris, Clinical Director, Memorial Sloan-Kettering Cancer Center in New York
Thursday, October 1, 2020
7:00 pm – 8:00 pm Eastern
About the Presenter
Dr. Michael Morris is prostate cancer specialist, clinical investigator, and the Section Head of Prostate Cancer of the Genitourinary Oncology Service at Memorial Sloan-Kettering Cancer Center. He earned his medical degree from the Mount Sinai School of Medicine in New York, and performed his internship and residency in Internal Medicine at Columbia Presbyterian Medical Center. He then completed his medical oncology fellowship at Memorial Sloan-Kettering Cancer Center, where he was the Chief Fellow as well.
Dr. Morris has led numerous clinical trials, but he has a particular research focus on targeted therapy for prostate cancer, especially those that bridge the fields of Medical Oncology and Nuclear Medicine. In the field of therapeutics, he has focused on radio immunotherapy and other radio-conjugates, bone directed therapy, and other targeted therapies. In the field of diagnostics, he has a keen research interest in developing novel imaging technologies for metastatic prostate cancer and in developing novel imaging biomarkers. He has been a co-developer of the Prostate Cancer Working Group 2 and 3 Consensus Criteria, and novel prostate-specific imaging technologies such as FDHT PET and PSMA-directed PET imaging.
In addition, he is the Medical Director of the Department of Prostate Cancer Clinical Consortium, and chairs the GU Committee of the Alliance for Oncology Trials in Oncology (formerly CALGB).
This Webinar is sponsored by: Progenics Pharmaceuticals